148 related articles for article (PubMed ID: 20963404)
1. Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers.
Sabo JP; Cong XJ; Kraft MF; Wallace L; Castles MA; Mauss S; MacGregor TR
Eur J Clin Pharmacol; 2011 Mar; 67(3):277-81. PubMed ID: 20963404
[TBL] [Abstract][Full Text] [Related]
2. Tipranavir: a novel nonpeptidic protease inhibitor of HIV.
King JR; Acosta EP
Clin Pharmacokinet; 2006; 45(7):665-82. PubMed ID: 16802849
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence studies of two different film-coated tablet formulations of valacyclovir of two different strengths in healthy volunteers.
Neves R; Almeida S; Filipe A; Spinola AC; Abolfathi Z; Lévesque A; Ortuño J; Torns A
Arzneimittelforschung; 2010; 60(5):273-81. PubMed ID: 20533765
[TBL] [Abstract][Full Text] [Related]
4. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.
Song I; Borland J; Chen S; Guta P; Lou Y; Wilfret D; Wajima T; Savina P; Peppercorn A; Castellino S; Wagner D; Hosking L; Mosteller M; Rubio JP; Piscitelli SC
Eur J Clin Pharmacol; 2014 Oct; 70(10):1173-9. PubMed ID: 25146692
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers.
Lin H; Tian Y; Tian JX; Zhang ZJ; Mao GG
Arzneimittelforschung; 2010; 60(3):162-7. PubMed ID: 20422949
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.
Wang LH; Schultz M; Weller S; Smiley ML; Blum MR
Antimicrob Agents Chemother; 1996 Jan; 40(1):80-5. PubMed ID: 8787884
[TBL] [Abstract][Full Text] [Related]
7. Tipranavir: a review of its use in the management of HIV infection.
Orman JS; Perry CM
Drugs; 2008; 68(10):1435-63. PubMed ID: 18578560
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.
Goebel FD; MacGregor TR; Sabo JP; Castles M; Johnson PA; Legg D; McCallister S
HIV Clin Trials; 2010; 11(1):28-38. PubMed ID: 20400409
[TBL] [Abstract][Full Text] [Related]
9. Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers.
la Porte CJ; Sabo JP; Elgadi M; Cameron DW
Antimicrob Agents Chemother; 2009 Jan; 53(1):162-73. PubMed ID: 19015362
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the pharmacokinetics of apricitabine in the presence and absence of ritonavir-boosted tipranavir: a phase I, open-label, controlled, single-centre study.
Cox S; Southby J; Linet O; Tackwell K; Borin M; Perry K
Clin Drug Investig; 2009; 29(11):721-8. PubMed ID: 19813775
[TBL] [Abstract][Full Text] [Related]
11. Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers.
Garraffo R; Lavrut T; Ferrando S; Durant J; Rouyrre N; MacGregor TR; Sabo JP; Dellamonica P
J Clin Pharmacol; 2011 Jul; 51(7):1071-8. PubMed ID: 21209236
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir.
Moltó J; Valle M; Santos JR; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Clotet B
AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1191-6. PubMed ID: 20860529
[TBL] [Abstract][Full Text] [Related]
13. Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.
Bruce RD; Moody DE; Fang WB; Chodkowski D; Andrews L; Friedland GH
Am J Drug Alcohol Abuse; 2011 Jul; 37(4):224-8. PubMed ID: 21438849
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses.
Garré B; Shebany K; Gryspeerdt A; Baert K; van der Meulen K; Nauwynck H; Deprez P; De Backer P; Croubels S
Antimicrob Agents Chemother; 2007 Dec; 51(12):4308-14. PubMed ID: 17846132
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.
Weller S; Blum MR; Doucette M; Burnette T; Cederberg DM; de Miranda P; Smiley ML
Clin Pharmacol Ther; 1993 Dec; 54(6):595-605. PubMed ID: 8275615
[TBL] [Abstract][Full Text] [Related]
16. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.
Chen L; Sabo JP; Philip E; Mao Y; Norris SH; MacGregor TR; Wruck JM; Garfinkel S; Castles M; Brinkman A; Valdez H
Antimicrob Agents Chemother; 2007 Jul; 51(7):2436-44. PubMed ID: 17485497
[TBL] [Abstract][Full Text] [Related]
17. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.
Sekar V; Lefebvre E; De Marez T; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
Clin Drug Investig; 2008; 28(8):479-85. PubMed ID: 18598093
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function.
Smith JP; Weller S; Johnson B; Nicotera J; Luther JM; Haas DW
Antimicrob Agents Chemother; 2010 Mar; 54(3):1146-51. PubMed ID: 20038622
[TBL] [Abstract][Full Text] [Related]
19. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
[TBL] [Abstract][Full Text] [Related]
20. An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children.
Nadal D; Leverger G; Sokal EM; Floret D; Perel Y; Leibundgut K; Weller S
J Infect Dis; 2002 Oct; 186 Suppl 1():S123-30. PubMed ID: 12353197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
